• Praluent® is a fully human monoclonal antibody1 that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) from binding to LDL-Rs, increasing the number of LDL-Rs available to remove LDL-C from the circulation.1,2

    Without PCSK9 inhibition, PCSK9 decreases the number of available LDL-Rs on liver cells, resulting in higher LDL-C levels in the bloodstream.1

    PCSK9 inhibition with Praluent® increases the number of available LDL-Rs, resulting in lower LDL-C levels in the bloodstream.1

    Effects with of PCSK9 inhibition with Praluent®

    Figure © Sanofi.


    Watch the video below to learn more about the mechanism of action for Praluent®

    Video Player is loading.
    Current Time 0:00
    Duration -:-
    Loaded: 0%
    Stream Type LIVE
    Remaining Time 0:00


    Learn more


    Learn more

    LDL-C=low-density lipoprotein cholesterol; LDL-R=low-density lipoprotein receptor; PCSK9i=proprotein convertase subtilisin/kexin type 9 inhibitor.

    1. Praluent® (alirocumab) European Summary of Product Characteristics. March 2019.
    2. Poirier S and Mayer G. Drug Des Devel Ther 2013;7:1135–1148.